Media stories about Mirati Therapeutics (NASDAQ:MRTX) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 44.6634026305066 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
Shares of Mirati Therapeutics (NASDAQ MRTX) opened at $27.95 on Tuesday. Mirati Therapeutics has a 1 year low of $2.70 and a 1 year high of $30.50. The stock has a market cap of $754.47, a PE ratio of -8.99 and a beta of 2.10.
Several research firms have recently weighed in on MRTX. HC Wainwright reaffirmed a “buy” rating on shares of Mirati Therapeutics in a report on Tuesday, November 7th. ValuEngine upgraded shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub upgraded shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Oppenheimer reiterated a “buy” rating and issued a $18.00 target price on shares of Mirati Therapeutics in a research report on Wednesday, November 22nd. Finally, Cowen assumed coverage on shares of Mirati Therapeutics in a research report on Thursday, December 21st. They issued an “outperform” rating for the company. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $14.75.
In other Mirati Therapeutics news, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was acquired at an average cost of $13.00 per share, for a total transaction of $8,450,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jamie Christensen sold 10,275 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $18.00, for a total transaction of $184,950.00. Following the sale, the senior vice president now owns 12,670 shares of the company’s stock, valued at $228,060. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,314 shares of company stock valued at $1,831,831. Company insiders own 5.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Mirati Therapeutics (MRTX) Stock Price” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-mirati-therapeutics-mrtx-share-price.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.